We are live on ! Find out more
NWBOW

Northwest Biotherapeutics, Inc.
NWBOW

Delisted

NWBOW was delisted on the 16th of December, 2016.

Back to rankings

2 hedge funds and large institutions have $256K invested in Northwest Biotherapeutics, Inc. in 2014 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

24% less capital invested

Capital invested by funds: $334K → $256K (-$78.8K)

50% less funds holding

Funds holding: 4 → 2 (-2)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

Holders
2
Holders Change
-2
Holders Change %
-50%
% of All Funds
0.06%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
U
UBS
Switzerland
-$10K
2
GSC
Ground Swell Capital
South Carolina
-$1K
Name Holding Trade Value Shares
Change 		Change in
Stake
Allianz Asset Management
1
Allianz Asset Management
Germany
$245K – – –
AIG
2
American International Group
New York
$10.5K – – –
U
3
UBS
Switzerland
– -$10K -2,732 Closed
GSC
4
Ground Swell Capital
South Carolina
– -$1K -199 Closed

NWBOW Hedge Fund Activity: Q3 2014 in Review

2 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Northwest Biotherapeutics, Inc. (NWBOW) for Q3 2014, worth a combined $256K — down 24% from $334K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of NWBOW and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was UBS, exiting entirely with an estimated $10K sold.

  • 2 institutional investors held Northwest Biotherapeutics, Inc. (NWBOW) as of Q3 2014, down from 4 in Q2 2014.
  • Funds reported $256K of Northwest Biotherapeutics, Inc. stock for Q3 2014, down 24% quarter-over-quarter.
  • 0 funds opened new Northwest Biotherapeutics, Inc. positions in Q3 2014 and 2 closed out, a net change of -2 holders.
  • The largest Northwest Biotherapeutics, Inc. seller in Q3 2014 was UBS, an estimated $10K sold.

Based on aggregated 13F filings for Q3 2014.